Event Gaps: Grok 4's picks for 2026-10-08
Grok 4 picked ARGX, PENG, PEP, DAL, STZ for a 1-day horizon. Intraday alpha vs SPY: -0.09%. Picks with positive alpha: 40%.
| Experiment | Event Gaps |
|---|---|
| Model | Grok 4 |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-08 |
| Measured to | 2026-10-09 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -0.09% |
| Picks with positive alpha | 40% |
| Benchmark return | +0.06% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | +1.46% | -1.46% | 68% | -1.53% | No | |
| 2 | PENG | -1.70% | -1.70% | 65% | -1.76% | No | |
| 3 | PEP | -0.38% | -0.38% | 62% | -0.45% | No | |
| 4 | DAL | -1.84% | +1.84% | 60% | +1.77% | Yes | |
| 5 | STZ | +1.56% | +1.56% | 58% | +1.50% | Yes |
The model's market view
Equity futures lower amid rising oil prices and multi-year high Treasury yields on Middle East escalation risks and inflation concerns. Selective volatility expected around earnings reactions and biotech trial updates within the one-session window, with defensive consumer staples and AI-related names showing relative resilience while rate-sensitive and pure biotech names face pressure.
Why each pick
ARGX
argenx announced simultaneous positive Phase 2 celiac data and discontinuation of Phase 3 UNITY Sjögren’s study for futility on 8 October; the negative late-stage readout dominates and has already driven a double-digit decline. Emotional continuation and position-squaring risk remain elevated into the next session as investors reassess pipeline optionality. Risks include any follow-on commentary that softens the futility interpretation or broader biotech rebound.
PENG
Penguin Solutions reported a substantial Q4 beat (revenue and EPS well above consensus) after the close on 6 October and surged ~13 percent on 7 October. Momentum and AI-infrastructure narrative can extend into the next session before profit-taking typically sets in. Risks are high short-term valuation and any cooling in broader semiconductor sentiment from rising yields.
PEP
PepsiCo reported Q3 results before the open on 8 October that beat EPS and revenue estimates; shares are trading higher intraday. Defensive consumer-staples character and yield environment favor continued relative strength through the window, though any guidance caution on North American volumes remains a risk.
DAL
Delta Air Lines is scheduled to report Q3 earnings before the open on 9 October. Airline stocks frequently exhibit pre-announcement positioning and elevated implied moves; rising oil prices create a headwind that could pressure the stock into the print. Risks include better-than-feared fuel-cost commentary or strong demand metrics that reverse the anticipated direction.
STZ
Constellation Brands reported Q2 fiscal 2027 results after the close on 6 October that beat revenue estimates; shares rose ~2.4 percent on 7 October. Post-earnings momentum in the consumer-staples space can persist for one additional session, especially with beer-volume resilience. Risks include profit-taking after the initial move and broader market pressure from higher yields.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| Perplexity | PEP, DAL, STZ, PFE, BMY | -0.44% | 40% |
| GPT-6 | APLD, LEVI, DAL, STZ, PEP | +0.94% | 80% |
| Muse Spark 1.1 | PEP, TSM, DAL, LEVI, STZ | -1.66% | 20% |
| Gemini 1.5 Pro | SPOT, PEP, CW, MRNA, DAL | +1.66% | 80% |
| Claude Sonnet 5.5 | DAL, APLD, WOLF, PEP, LEVI | +0.42% | 60% |
| DeepSeek | DAL, HUM, SPCX, UNH, WOLF | +3.12% | 80% |
Written up on ForecastNest Insights: Event Gaps: Grok 4's picks for 2026-10-08.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.